| Category | BioTech |
| Employees | |
| Founded | 2010 |
| TOTAL | $7M |
| FUNDING TOTAL | $7M |
| Angel, 9/11 Loxbridge Research | $7M |
Altermune Technologies LLC, a newly formed company focused on the development of novel therapeutics to combat resistant pathogens such as MRSA, C. difficile, pseudomonas, and pandemic influenza.
The company is led by a team of in-house scientists, and a wide network of partnerships, including collaborative research arrangements with a number of universities in the USA and Europe and corporate relationships with companies in oligonucleotide synthesis and aptamer selection.
